 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today provided an update on OPC1, the Companys oligodendrocyte progenitor cell OPC therapy for the treatment of acute spinal cord injury SCI. The OPC1 program was obtained through Lineages acquisition of Asterias Biopharmaceuticals in March 2019, and manufacturing has been completely transferred to the Companys current Good Manufacturing Practice cGMP facility in Israel, where key process improvements have been developed and implemented. Lineage also has strengthened its patent position in order to protect the OPC1 processes, product and composition, and methods of use. Lineage intends to meet with the U.S. Food and Drug Administration FDA to discuss further development of the OPC1 program by the end of 2020. 